**Executive Summary**
The Promotion of Research and Innovation in Pharma MedTech Sector (PRIP) scheme aims to transform the Indian Pharma MedTech sector from a cost-based to innovation-based growth model by strengthening research infrastructure. The scheme has two components: strengthening research infrastructure (Component A) and promoting research and innovation (Component B). The Department of Pharmaceuticals has invited applications under Component B from the pharmaceutical and MedTech industry and startups.
**Key Points / Main Content**
* **Scheme Objective:**
* Transform the Indian Pharma MedTech sector to innovation-based growth.
* **Scheme Components:**
* **Component A:** Strengthening research infrastructure through Centers of Excellence at seven NIPERs (Mohali, Ahmedabad, Guwahati, Kolkata, Raebareli, Hajipur and Hyderabad).
* **Component B:** Providing financial assistance for R&D, product/technology development, and validation in new medicines, complex generics/biosimilars, and novel medical devices.
* **Component A Details:**
* Institutional strengthening of research infrastructure at the seven NIPERs.
* Focus on postgraduate/doctoral education and high-end research.
* Specializations include antiviral/antibacterial drug discovery, medical devices, bulk drugs, and more.
* Aims to build research capacities and promote industry-academia linkage.
* **Component B Details:**
* Encourages industry and startups to collaborate with academic/research institutions.
* Supports the development, translation, and commercialization of institutional intellectual property.
* Aims to augment institutional research capacities.
* **Financial Assistance (Component B):**
* **Early Stage Projects (MSMEs/Startups):** Projects costing up to ₹9 crore, assistance up to ₹5 crore. 100% for cost up to 1 crore and 50% of additional cost beyond ₹1 crore, subject to a maximum up to 5 crore.
* **Later Stage Projects (Industry/MSMEs/Startups):** Projects costing up to ₹285 crore, assistance up to ₹100 crore. 35% of the project cost (50% for Strategic Priority Innovation areas), subject to a maximum of ₹100 crore.
* **Strategic Priority Innovation Areas:**
* Address areas of India's public health concern with relatively lower market potential.
* Financial assistance for Later Stage Projects may be up to 50% of the approved total project cost (subject to a maximum of ₹100 crore), compared to 35% for other areas.
**Impact Analysis**
**MSMEs and Startups**
* **Impact:** Eligible for financial assistance for both Early and Later Stage Projects under Component B.
* **Action Required:** Apply for projects aligning with PRIP scheme guidelines to receive financial assistance for R&D and commercialization.
**Pharmaceutical and MedTech Industry**
* **Impact:** Eligible for financial assistance for Later Stage Projects under Component B. Can collaborate with academic/research institutions.
* **Action Required:** Apply for projects aligning with PRIP scheme guidelines to receive financial assistance for R&D and commercialization.
**National Institutes of Pharmaceutical Education and Research (NIPERs)**
* **Impact:** Designated as Centers of Excellence under Component A, receiving support for strengthening research infrastructure.
* **Action Required:** Enhance research capabilities and promote industry-academia collaboration to contribute to the growth of the Pharma MedTech sector.
**Government Academic and Research Institutions**
* **Impact:** Can collaborate with industry and startups under Component B to support R&D and commercialization.
* **Action Required:** Partner with industry and startups on research projects.
Key Entities Referenced
PRIP Scheme: Promotion of Research and Innovation in Pharma MedTech Sector scheme to transform Indian Pharma MedTech sector from cost based to innovation-based growth.
Department of Pharmaceuticals: Under the Ministry of Chemicals and Fertilizers, this department is implementing PRIP.
NIPERs: National Institute of Pharmaceutical Education and Research; centers of excellence established at seven locations in India under Component A of the PRIP scheme.
Ministry of Chemicals and Fertilizers :
Department of Pharmaceuticals
PRIP Scheme aims to transform Indian
PharmaMedTech Sector through innovation
based growth by strengthening research
infrastructure
प्रव तथ: 09 DEC 2025 5:22PM by PIB Delhi
The objective of the Promotion of Research and Innovation in Pharma MedTech Sector (PRIP) scheme is
to transform Indian Pharma MedTech sector from cost based to innovation-based growth by strengthening
the research infrastructure in the country. The rationale behind the recent amendments was to facilitate
smooth implementation, bring greater clarity in governance and make benefit-sharing mechanisms more
effective. Key features of the scheme are as under:
i. It has two components, namely, Component A: Strengthening the research infrastructure through
setting up of centres of excellence at National Institute of Pharmaceutical Education and Research
(NIPERs) and Component B: Promotion of Research and Innovation in Pharma MedTech sector.
ii. Under component A, a total of seven centres of excellence have been set up, one at each of the
seven NIPERs established at Mohali, Ahmedabad, Guwahati, Kolkata, Raebareli, Hajipur and
Hyderabad.
iii. Component B is for providing financial assistance to support research and development (R&D) for
development of products and technologies (outputs) or expeditious validation of R&D outputs for
market launch and large-scale commercialisation in three priority areas, namely new medicines,
complex generics and biosimilars, and novel medical devices. Under this component, the
Department of Pharmaceuticals has invited applications for research and innovation projects from
pharmaceutical and MedTech industry and startups.
Under component B of the scheme, for Early Stage Projects, MSMEs and startups may apply for projects
costing up to ₹9 crore for assistance of up to ₹5 crore. For Later Stage Projects, projects of industry,
MSMEs and startups costing up to ₹285 crore may apply for assistance up to ₹100 crore. The scale of
financial assistance for Early Stage Projects is 100% for cost up to ₹1 crore and 50% of additional cost
beyond ₹1 crore, subject to a maximum up to ₹5 crore. The scale for financial assistance for Later Stage
Projects is 35% of the project cost (50% in case of projects in Strategic Priority Innovation areas), subject
to a maximum of ₹100 crore.
The criteria adopted for inclusion of projects in Strategic Priority Innovation areas is that they address
areas of India’s public health concern for which market potential is relatively lower. For Later Stage
Projects in these areas, financial assistance may be to the extent of 50% of the approved total project cost,
as against 35% for projects in other areas, subject to a maximum of ₹100 crore.
Mechanisms under the scheme to institutionally promote the national pharma-medtech innovation
ecosystem include the following:i. Under component A, institutional strengthening of research infrastructure has been undertaken
through the setting up of centres of excellence at the seven National Institutes of Pharmaceutical
Education and Research, which are institutes of national importance for imparting postgraduate and
doctoral education and conduct high-end research in various specialisations in pharmaceutical
sciences and medical technologies. These centres are in the specialisations of anti-viral and anti-
bacterial drug discovery and development, medical devices, bulk drugs, flow chemistry and
continuous manufacturing, novel drug delivery system, phyto-pharmaceuticals and biological
therapeutics, with a view to help in building specific research capacities in the identified priority
areas, tapping industry-academia linkage. These are aimed at strengthening the research
infrastructure in the pharma-MedTech sector by providing advanced facilities to conduct research
and help in nurturing talent pool by promoting industry-academia linkage.
ii. Under component B, industry and startups are encouraged under the scheme to collaborate flexibly
with reputed Government academic and research institutions specified in the Scheme guidelines to
develop, translate and commercialise institutional intellectual property and to augment institutional
research capacities in India.
This information was given by Union Minister of State in the Ministry of Chemicals and Fertilizers,
Smt. Anupriya Patel, in a written reply in Rajya Sabha today.
******
PC/NK/PM
(रलीज़ आईडी: 2200936) आगंतुक पटल : 477
इस वज्ञ को इन भाषाओ ंम पढ़: Urdu , ही